CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-01 | Loerop James Chief Business Officer | Shares withheld for taxes | −15,447 | $2.48 | $38K | 103,306 |
| 2025-02-01 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Units | −11,250 | 11,250 | ||
| 2025-02-01 | Loerop James Chief Business Officer | Option exercise · Resticted Stock Units | −7,500 | 15,000 | ||
| 2025-02-01 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Units | −14,750 | 44,250 | ||
| 2025-01-02 | Monahan Joseph Chief Scientific Officer | Option exercise | +17,380 | 229,976 | ||
| 2025-01-02 | Monahan Joseph Chief Scientific Officer | Shares withheld for taxes | −8,914 | 221,062 | ||
| 2025-01-02 | Monahan Joseph Chief Scientific Officer | Grant or award · Restricted Stock Units | +52,667 | 52,667 | ||
| 2025-01-02 | Monahan Joseph Chief Scientific Officer | Option exercise · Restricted Stock Units | −17,380 | 35,287 | ||
| 2025-01-02 | Balthaser Kevin Chief Financial Officer | Option exercise | +13,200 | 85,985 | ||
| 2025-01-02 | Balthaser Kevin Chief Financial Officer | Shares withheld for taxes | −5,059 | $2.48 | $13K | 80,926 |
| 2025-01-02 | Balthaser Kevin Chief Financial Officer | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2025-01-02 | Balthaser Kevin Chief Financial Officer | Option exercise · Restricted Stock Units | −13,200 | 26,800 | ||
| 2025-01-02 | Loerop James Chief Business Officer | Option exercise | +18,150 | 93,828 | ||
| 2025-01-02 | Loerop James Chief Business Officer | Shares withheld for taxes | −8,575 | $2.48 | $21K | 85,253 |
| 2025-01-02 | Loerop James Chief Business Officer | Grant or award · Restricted Stock Units | +55,000 | 55,000 | ||
| 2025-01-02 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Units | −18,150 | 36,850 | ||
| 2025-01-02 | Walker Neal INTERIM CEO | Option exercise | +29,149 | 1,468,342 | ||
| 2025-01-02 | Walker Neal INTERIM CEO | Shares withheld for taxes | −13,532 | $2.48 | $34K | 1,454,810 |
| 2025-01-02 | Walker Neal INTERIM CEO | Grant or award · Restricted Stock Units | +88,333 | 88,333 | ||
| 2025-01-02 | Walker Neal INTERIM CEO | Option exercise · Restricted Stock Units | −29,149 | 59,184 |
Page 9 of 34 · 680 trades